Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Faries

Showing results (11-20 of 41) with videos related to

Pageof 5
Sort By:
Applied Health Economics and Health Policy|March 30, 2013
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparisonCarlos I Alatorre, Virginia Haynes, Douglas Faries, et al.
BMC Psychiatry|June 1, 2005
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychoticsDouglas Faries, Haya Ascher-Svanum, Baojin Zhu, et al.
BMC Psychiatry|July 31, 2009
Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patientsHaya Ascher-Svanum, Xiaomei Peng, Douglas Faries, et al.
Journal of Child and Adolescent Psychopharmacology|March 5, 2008
The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder--Child Version: psychometric properties of an adaptive change instrumentKeith Saylor, Curt Buermeyer, Virginia Sutton, et al.
Biometrika|April 7, 2025
Improving randomized controlled trial analysis via data-adaptive borrowingChenyin Gao, Shu Yang, Mingyang Shan, et al.
Journal of Psychosomatic Research|May 24, 2016
Covariates of depression and high utilizers of healthcare: Impact on resource use and costsRebecca L Robinson, Michael Grabner, Swetha Rao Palli, et al.
Schizophrenia Research|February 10, 2012
Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trialStephen Z Levine, Jonathan Rabinowitz, Douglas Faries, et al.
The Journal of Clinical Psychiatry|August 8, 2006
A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophreniaHaya Ascher-Svanum, Baojin Zhu, Douglas Faries, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophreniaXiaomei Peng, Haya Ascher-Svanum, Douglas Faries, et al.
BMC Psychiatry|March 1, 2006
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophreniaHaya Ascher-Svanum, Baojin Zhu, Douglas Faries, et al.
Pageof 5

Showing results (11-20 of 41) with videos related to

Sort By:
Pageof 5
Applied Health Economics and Health Policy|March 30, 2013
Cost effectiveness of guanfacine extended-release versus atomoxetine for the treatment of attention-deficit/hyperactivity disorder: application of a matching-adjusted indirect comparisonCarlos I Alatorre, Virginia Haynes, Douglas Faries, et al.
BMC Psychiatry|June 1, 2005
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychoticsDouglas Faries, Haya Ascher-Svanum, Baojin Zhu, et al.
BMC Psychiatry|July 31, 2009
Treatment patterns and clinical characteristics prior to initiating depot typical antipsychotics for nonadherent schizophrenia patientsHaya Ascher-Svanum, Xiaomei Peng, Douglas Faries, et al.
Journal of Child and Adolescent Psychopharmacology|March 5, 2008
The Life Participation Scale for Attention-Deficit/Hyperactivity Disorder--Child Version: psychometric properties of an adaptive change instrumentKeith Saylor, Curt Buermeyer, Virginia Sutton, et al.
Biometrika|April 7, 2025
Improving randomized controlled trial analysis via data-adaptive borrowingChenyin Gao, Shu Yang, Mingyang Shan, et al.
Journal of Psychosomatic Research|May 24, 2016
Covariates of depression and high utilizers of healthcare: Impact on resource use and costsRebecca L Robinson, Michael Grabner, Swetha Rao Palli, et al.
Schizophrenia Research|February 10, 2012
Treatment response trajectories and antipsychotic medications: examination of up to 18 months of treatment in the CATIE chronic schizophrenia trialStephen Z Levine, Jonathan Rabinowitz, Douglas Faries, et al.
The Journal of Clinical Psychiatry|August 8, 2006
A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophreniaHaya Ascher-Svanum, Baojin Zhu, Douglas Faries, et al.
Clinicoeconomics and Outcomes Research : CEOR|September 22, 2011
Decline in hospitalization risk and health care cost after initiation of depot antipsychotics in the treatment of schizophreniaXiaomei Peng, Haya Ascher-Svanum, Douglas Faries, et al.
BMC Psychiatry|March 1, 2006
Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophreniaHaya Ascher-Svanum, Baojin Zhu, Douglas Faries, et al.
Pageof 5